Comparison of Different Acellular Dermal Matrices in Breast Reconstruction: The 50/50 Study.

摘要: BACKGROUND Acellular dermal matrix has enjoyed extensive use in primary and secondary alloplastic breast aesthetic reconstructive surgery. The objective of this study was to examine clinical outcomes between available acellular products: DermACELL (LifeNet Health, Virginia Beach, Va.) AlloDerm Ready To Use (LifeCell Corp., Branchburg, N.J.). METHODS A retrospective chart review performed on 58 consecutive patients (100 breasts) reconstructed with either (n = 30 patients; 50 or 28 breasts). mastectomies were by three different surgeons. All reconstructions the same plastic surgeon (T.A.P.). Statistical analysis means Fisher's exact test. RESULTS Differences average age, body mass index, percentage having neoadjuvant/adjuvant chemotherapy irradiation, numbers therapeutic prophylactic two groups not statistically significant (p < 0.05). Complications both cohorts clinically recorded for 90 days after immediate reconstruction. When comparing outcomes, group had a significantly lower incidence "red syndrome" (0 percent versus 26 percent; p 0.0001) fewer before drain removal (15.8 20.6 days; 0.017). No differences seen terms seroma, hematoma, delayed healing, infection, flap necrosis, explantation. CONCLUSION Patients as compared have decreased number red syndrome equivalent rates other complications, including CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, III.